Predict your next investment

Aelix Therapeutics company logo
HEALTHCARE | Drug Development
aelixtherapeutics.com

See what CB Insights has to offer

Executives

5

Board of Directors

3

Aelix Therapeutics Board of Directors

3 Board of directors

Aelix Therapeutics has 3 board of directors, including Jeanne Bolger.

Name

Firm

Work History

Other Seats

Jeanne Bolger

Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. In 2012, upon the establishment of the Innovation Centers, Dr Bolger joined J&J’s corporate venture fund, Johnson & Johnson Innovation – JJDC. She is based in London with responsibility for investments across Europe in start-up and early stage life science companies in areas of strategic interest to J&J’s business sectors in Pharmaceuticals and Biotechnology, Medical Devices and Consumer. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

Asceneuron, Biocartis, Calypso Biotech, Inivata, Merus, Pulmocide, and S-Biomedic

Jordi Naval

Jose Mesa

Accure Therapeutics, Minoryx Therapeutics, Ona Therapeutics, Sanifit, and STAT-Dx

Name

Jeanne Bolger

Jordi Naval

Jose Mesa

Firm

Work History

Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. In 2012, upon the establishment of the Innovation Centers, Dr Bolger joined J&J’s corporate venture fund, Johnson & Johnson Innovation – JJDC. She is based in London with responsibility for investments across Europe in start-up and early stage life science companies in areas of strategic interest to J&J’s business sectors in Pharmaceuticals and Biotechnology, Medical Devices and Consumer. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

Other Seats

Asceneuron, Biocartis, Calypso Biotech, Inivata, Merus, Pulmocide, and S-Biomedic

Accure Therapeutics, Minoryx Therapeutics, Ona Therapeutics, Sanifit, and STAT-Dx

Aelix Therapeutics Management Team

5 Team Members

Aelix Therapeutics has 5 executives. Aelix Therapeutics's founder is Christian Brander. Aelix Therapeutics's current Chief Financial Officer is Yves Mertens.

Name

Work History

Title

Status

Christian Brander

Founder

Current

Bonaventura Clotet

Founder

Current

Jordi Naval

Founder

Current

Yves Mertens

Etex

Chief Financial Officer

Current

Ian McGowan

Chief Medical Officer

Former

Name

Christian Brander

Bonaventura Clotet

Jordi Naval

Yves Mertens

Ian McGowan

Work History

Etex

Title

Founder

Founder

Founder

Chief Financial Officer

Chief Medical Officer

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.